A Multicenter Retrospective Cohort Study of Practice Patterns and Clinical Outcomes of the Use of Darbepoetin Alfa and Epoetin Alfa for Chemotherapy-Induced Anemia

Lee Schwartzberg, Roger Shiftman, Dianne Tomita, Bradley Stolshek, Greg Rossi, Robert Adamson

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Darbepoetin alfa is the second erythropoietic protein to be approved for the treatment of chemotherapy-induced anemia (CIA). In the clinical setting, darbepoetin alfa can be administered less frequently than epoetin alfa with similar efficacy. Practice patterns and outcomes associated with the use of darbepoetin alfa and epoetin alfa in the clinical setting have not been reported. Objective: This study compared practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for CIA at oncology practices in the United States. Methods: This was a multicenter retrospective cohort study. Data were abstracted from the medical charts of consecutive patients who began darbepoetin alfa treatment between August 1 and October 4, 2002, or epoetin alfa treatment between April 1 and July 31, 2002, and were receiving concurrent chemotherapy. These data were used to determine the initial dose and dosing schedule, dose changes, and changes in hemoglobin concentrations after 4, 8, and 12 weeks of treatment, adjusted for red blood cell (RBC) transfusions, and the incidence of RBC transfusions over time. To minimize potential bias, the study protocol defined specific end points and prespecified analytic techniques for assessing clinical outcomes with the 2 agents. Results: The records of 1391 patients from 16 community and hospital outpatient oncology clinics were abstracted. Of these, 1293 patients (93.0%) received only 1 erythropoietic agent (darbepoetin alfa, 735 [56.8%]; epoetin alfa, 558 [43.2%]); the remainder received both agents. In the patients who received darbepoetin alfa, most (553 [75.2%]) received an initial dosage of 200 μg q2wk. A similar proportion (414 [74.2%]) received epoetin alfa at an initial dosage of 40,000 U qwk. As these were the regimens for the majority of patients whose records were abstracted, the results reported here are for these patients. The dose was increased in 63 darbepoetin alfa recipients (11.4%) and 58 epoetin alfa recipients (14.0%) at a median of 7 weeks. After 12 weeks, the 2 groups had an identical mean imputed change from baseline in hemoglobin concentration (1.0 g/dL), and the incidence of RBC transfusions during treatment was also similar between groups (darbepoetin alfa, 44/553 [8.0%]; epoetin alfa, 39/414 [9.4%]). Conclusions: Darbepoetin alfa 200 μg q2wk was used as a standard regimen for CIA at the 16 US oncology practices participating in this study. It appeared to be as effective as epoetin alfa 40,000 U qwk, with a reduced frequency of dosing.

Original languageEnglish (US)
Pages (from-to)2781-2796
Number of pages16
JournalClinical Therapeutics
Volume25
Issue number11
DOIs
StatePublished - Jan 1 2003

Fingerprint

Epoetin Alfa
Physicians' Practice Patterns
Anemia
Cohort Studies
Retrospective Studies
Drug Therapy
Erythrocyte Transfusion
Hemoglobins
Darbepoetin alfa
Hospital Outpatient Clinics
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

A Multicenter Retrospective Cohort Study of Practice Patterns and Clinical Outcomes of the Use of Darbepoetin Alfa and Epoetin Alfa for Chemotherapy-Induced Anemia. / Schwartzberg, Lee; Shiftman, Roger; Tomita, Dianne; Stolshek, Bradley; Rossi, Greg; Adamson, Robert.

In: Clinical Therapeutics, Vol. 25, No. 11, 01.01.2003, p. 2781-2796.

Research output: Contribution to journalArticle

Schwartzberg, Lee ; Shiftman, Roger ; Tomita, Dianne ; Stolshek, Bradley ; Rossi, Greg ; Adamson, Robert. / A Multicenter Retrospective Cohort Study of Practice Patterns and Clinical Outcomes of the Use of Darbepoetin Alfa and Epoetin Alfa for Chemotherapy-Induced Anemia. In: Clinical Therapeutics. 2003 ; Vol. 25, No. 11. pp. 2781-2796.
@article{063b72d43a97428a964c5215fa41af07,
title = "A Multicenter Retrospective Cohort Study of Practice Patterns and Clinical Outcomes of the Use of Darbepoetin Alfa and Epoetin Alfa for Chemotherapy-Induced Anemia",
abstract = "Background: Darbepoetin alfa is the second erythropoietic protein to be approved for the treatment of chemotherapy-induced anemia (CIA). In the clinical setting, darbepoetin alfa can be administered less frequently than epoetin alfa with similar efficacy. Practice patterns and outcomes associated with the use of darbepoetin alfa and epoetin alfa in the clinical setting have not been reported. Objective: This study compared practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for CIA at oncology practices in the United States. Methods: This was a multicenter retrospective cohort study. Data were abstracted from the medical charts of consecutive patients who began darbepoetin alfa treatment between August 1 and October 4, 2002, or epoetin alfa treatment between April 1 and July 31, 2002, and were receiving concurrent chemotherapy. These data were used to determine the initial dose and dosing schedule, dose changes, and changes in hemoglobin concentrations after 4, 8, and 12 weeks of treatment, adjusted for red blood cell (RBC) transfusions, and the incidence of RBC transfusions over time. To minimize potential bias, the study protocol defined specific end points and prespecified analytic techniques for assessing clinical outcomes with the 2 agents. Results: The records of 1391 patients from 16 community and hospital outpatient oncology clinics were abstracted. Of these, 1293 patients (93.0{\%}) received only 1 erythropoietic agent (darbepoetin alfa, 735 [56.8{\%}]; epoetin alfa, 558 [43.2{\%}]); the remainder received both agents. In the patients who received darbepoetin alfa, most (553 [75.2{\%}]) received an initial dosage of 200 μg q2wk. A similar proportion (414 [74.2{\%}]) received epoetin alfa at an initial dosage of 40,000 U qwk. As these were the regimens for the majority of patients whose records were abstracted, the results reported here are for these patients. The dose was increased in 63 darbepoetin alfa recipients (11.4{\%}) and 58 epoetin alfa recipients (14.0{\%}) at a median of 7 weeks. After 12 weeks, the 2 groups had an identical mean imputed change from baseline in hemoglobin concentration (1.0 g/dL), and the incidence of RBC transfusions during treatment was also similar between groups (darbepoetin alfa, 44/553 [8.0{\%}]; epoetin alfa, 39/414 [9.4{\%}]). Conclusions: Darbepoetin alfa 200 μg q2wk was used as a standard regimen for CIA at the 16 US oncology practices participating in this study. It appeared to be as effective as epoetin alfa 40,000 U qwk, with a reduced frequency of dosing.",
author = "Lee Schwartzberg and Roger Shiftman and Dianne Tomita and Bradley Stolshek and Greg Rossi and Robert Adamson",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S0149-2918(03)80333-8",
language = "English (US)",
volume = "25",
pages = "2781--2796",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "11",

}

TY - JOUR

T1 - A Multicenter Retrospective Cohort Study of Practice Patterns and Clinical Outcomes of the Use of Darbepoetin Alfa and Epoetin Alfa for Chemotherapy-Induced Anemia

AU - Schwartzberg, Lee

AU - Shiftman, Roger

AU - Tomita, Dianne

AU - Stolshek, Bradley

AU - Rossi, Greg

AU - Adamson, Robert

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Background: Darbepoetin alfa is the second erythropoietic protein to be approved for the treatment of chemotherapy-induced anemia (CIA). In the clinical setting, darbepoetin alfa can be administered less frequently than epoetin alfa with similar efficacy. Practice patterns and outcomes associated with the use of darbepoetin alfa and epoetin alfa in the clinical setting have not been reported. Objective: This study compared practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for CIA at oncology practices in the United States. Methods: This was a multicenter retrospective cohort study. Data were abstracted from the medical charts of consecutive patients who began darbepoetin alfa treatment between August 1 and October 4, 2002, or epoetin alfa treatment between April 1 and July 31, 2002, and were receiving concurrent chemotherapy. These data were used to determine the initial dose and dosing schedule, dose changes, and changes in hemoglobin concentrations after 4, 8, and 12 weeks of treatment, adjusted for red blood cell (RBC) transfusions, and the incidence of RBC transfusions over time. To minimize potential bias, the study protocol defined specific end points and prespecified analytic techniques for assessing clinical outcomes with the 2 agents. Results: The records of 1391 patients from 16 community and hospital outpatient oncology clinics were abstracted. Of these, 1293 patients (93.0%) received only 1 erythropoietic agent (darbepoetin alfa, 735 [56.8%]; epoetin alfa, 558 [43.2%]); the remainder received both agents. In the patients who received darbepoetin alfa, most (553 [75.2%]) received an initial dosage of 200 μg q2wk. A similar proportion (414 [74.2%]) received epoetin alfa at an initial dosage of 40,000 U qwk. As these were the regimens for the majority of patients whose records were abstracted, the results reported here are for these patients. The dose was increased in 63 darbepoetin alfa recipients (11.4%) and 58 epoetin alfa recipients (14.0%) at a median of 7 weeks. After 12 weeks, the 2 groups had an identical mean imputed change from baseline in hemoglobin concentration (1.0 g/dL), and the incidence of RBC transfusions during treatment was also similar between groups (darbepoetin alfa, 44/553 [8.0%]; epoetin alfa, 39/414 [9.4%]). Conclusions: Darbepoetin alfa 200 μg q2wk was used as a standard regimen for CIA at the 16 US oncology practices participating in this study. It appeared to be as effective as epoetin alfa 40,000 U qwk, with a reduced frequency of dosing.

AB - Background: Darbepoetin alfa is the second erythropoietic protein to be approved for the treatment of chemotherapy-induced anemia (CIA). In the clinical setting, darbepoetin alfa can be administered less frequently than epoetin alfa with similar efficacy. Practice patterns and outcomes associated with the use of darbepoetin alfa and epoetin alfa in the clinical setting have not been reported. Objective: This study compared practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for CIA at oncology practices in the United States. Methods: This was a multicenter retrospective cohort study. Data were abstracted from the medical charts of consecutive patients who began darbepoetin alfa treatment between August 1 and October 4, 2002, or epoetin alfa treatment between April 1 and July 31, 2002, and were receiving concurrent chemotherapy. These data were used to determine the initial dose and dosing schedule, dose changes, and changes in hemoglobin concentrations after 4, 8, and 12 weeks of treatment, adjusted for red blood cell (RBC) transfusions, and the incidence of RBC transfusions over time. To minimize potential bias, the study protocol defined specific end points and prespecified analytic techniques for assessing clinical outcomes with the 2 agents. Results: The records of 1391 patients from 16 community and hospital outpatient oncology clinics were abstracted. Of these, 1293 patients (93.0%) received only 1 erythropoietic agent (darbepoetin alfa, 735 [56.8%]; epoetin alfa, 558 [43.2%]); the remainder received both agents. In the patients who received darbepoetin alfa, most (553 [75.2%]) received an initial dosage of 200 μg q2wk. A similar proportion (414 [74.2%]) received epoetin alfa at an initial dosage of 40,000 U qwk. As these were the regimens for the majority of patients whose records were abstracted, the results reported here are for these patients. The dose was increased in 63 darbepoetin alfa recipients (11.4%) and 58 epoetin alfa recipients (14.0%) at a median of 7 weeks. After 12 weeks, the 2 groups had an identical mean imputed change from baseline in hemoglobin concentration (1.0 g/dL), and the incidence of RBC transfusions during treatment was also similar between groups (darbepoetin alfa, 44/553 [8.0%]; epoetin alfa, 39/414 [9.4%]). Conclusions: Darbepoetin alfa 200 μg q2wk was used as a standard regimen for CIA at the 16 US oncology practices participating in this study. It appeared to be as effective as epoetin alfa 40,000 U qwk, with a reduced frequency of dosing.

UR - http://www.scopus.com/inward/record.url?scp=0344664553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344664553&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(03)80333-8

DO - 10.1016/S0149-2918(03)80333-8

M3 - Article

VL - 25

SP - 2781

EP - 2796

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 11

ER -